Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biopsy needle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    254 result(s) found for: Biopsy needle. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-002179-12 Sponsor Protocol Number: PRILODE50-FUSION Start Date*: 2022-09-16
    Sponsor Name:Matilde Zaballos
    Full Title: Determination of the effective dose 50 of intrathecal hyperbaric prilocaine required for the transrectal ultrasound guidance fusion-targeted prostate biopsy in ambulatory surgery
    Medical condition: anaesthesia for prostate fusion biopsy in outpatient surgery
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10004825 Biopsy of prostate LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003740-39 Sponsor Protocol Number: URO-CHUAC-BPSat-001. Start Date*: 2016-04-12
    Sponsor Name:Jose Luis Ponce Díaz-Reixa
    Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy .
    Medical condition: Prostate biopsy anesthesia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10004825 Biopsy of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006647-99 Sponsor Protocol Number: 2021/ABM/01/00010 Start Date*: 2022-03-02
    Sponsor Name:Medical University of Bialystok
    Full Title: Safety Outcomes Post kidney Biopsy – randomized Clinical Evaluation of Efficacy of Desmopressin
    Medical condition: Rare and ultra-rare glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018364 Glomerulonephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003582-18 Sponsor Protocol Number: 20190009 Start Date*: 2020-05-18
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC S...
    Medical condition: Previously treated locally advanced and unresectable or metastatic nonsmall cell lung cancer (NSCLC) with KRAS p.G12C mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FR (Trial now transitioned) DK (Completed) PL (Trial now transitioned) FI (Completed) BE (Completed) PT (Completed) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) HU (Completed) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000403-33 Sponsor Protocol Number: GEICAM/2004-04 Start Date*: 2005-06-01
    Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM)
    Full Title: Randomized clinical trial to evaluate the predictive accuracy of a gene expression profile-based test to select patients for preoperative taxane/anthracycline chemotherapy for stage I-III breast ca...
    Medical condition: Patients with histologically confirmed stage I-III invasive carcinoma of the breast for whom adjuvant chemotherapy is indicated.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016686-28 Sponsor Protocol Number: 18F-FCH Start Date*: 2010-04-14
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Evaluation of [18F]Fluorocholine PET/CT imaging for staging and restaging of prostate cancer
    Medical condition: PATIENTS AFFECTED BY PROSTATIC CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036222 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005715-22 Sponsor Protocol Number: D6990C00001 Start Date*: 2006-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone ma...
    Medical condition: postmenopausal women with hormone receptor positive early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) NO (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002991-15 Sponsor Protocol Number: SOLTI-1804 Start Date*: 2019-11-04
    Sponsor Name:SOLTI
    Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302
    Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001417-18 Sponsor Protocol Number: DTS-301CLI001 Start Date*: 2005-09-27
    Sponsor Name:DIATOS S.A.
    Full Title: A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast Cancer
    Medical condition: Invasive primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003064-47 Sponsor Protocol Number: CUDC-101-104 Start Date*: 2012-12-11
    Sponsor Name:Curis, Inc.
    Full Title: A Phase 1 open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer.
    Medical condition: HER2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004758-33 Sponsor Protocol Number: Rapid-study Start Date*: 2015-09-08
    Sponsor Name:Medical University of Vienna
    Full Title: Randomized Assessment of patients with clinically suspected Prostate cancer after multiparametric metabolic hybrid Imaging to evaluate its potential clinical Domain: A prospective, randomized, mult...
    Medical condition: Clinical suspected prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004190-12 Sponsor Protocol Number: MK8808-003 Start Date*: 2013-03-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera™ in Patients with Advanced CD20-Positive Follicular Lymphoma.
    Medical condition: Previously untreated patients with CD20-positive follicular lymphoma, Grade 1, 2 or 3a according to the WHO 2008 classification system.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10059432 Follicular mixed small and large cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001016-51 Sponsor Protocol Number: 05-UTROGEL-01 Start Date*: 2006-02-28
    Sponsor Name:Karolinska Hospital
    Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study
    Medical condition: Menopausal symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001066-15 Sponsor Protocol Number: LR19912019 Start Date*: 2019-08-16
    Sponsor Name:Merete Hædersdal
    Full Title: Treatment of hypertrophic scars using needle-free jet-injection of triamcinolone and 5-Fluorouracile: a prospective, controlled, randomized, single-blinded split-lesion trial.
    Medical condition: Hypertrophic scars on 20 participants
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10070845 Skin scarring LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002806-28 Sponsor Protocol Number: SOLTI-1502 Start Date*: 2019-10-25
    Sponsor Name:SOLTI
    Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
    Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001316-38 Sponsor Protocol Number: UR1909 Start Date*: 2019-11-20
    Sponsor Name:Department of Oncology, Herlev University Hospital
    Full Title: A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
    Medical condition: Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066352 Renal cell carcinoma with sarcomatoid features LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078493 Papillary renal cell carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029508 Non-renal cell carcinoma of kidney NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003554-23 Sponsor Protocol Number: NL68976.041.19 Start Date*: 2021-12-03
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection in early-stage ORal Cavity squamous cell carcinoma using Magnetic Resonance (MR) lymphogrAphy
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with early-stage oral cavity squamous cell carcinoma and a clinically negative neck (T1-3, N0, M0).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10004822 Biopsy of lymph node LLT
    21.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003612-45 Sponsor Protocol Number: A9001502 Start Date*: 2019-09-06
    Sponsor Name:Pfizer Inc.
    Full Title: TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000358-21 Sponsor Protocol Number: D7919C00706 (ZD1839IL/0706) Start Date*: 2004-10-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiother...
    Medical condition: Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003126-25 Sponsor Protocol Number: MS201923-0001 Start Date*: 2012-09-27
    Sponsor Name:Merck KGaA
    Full Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
    Medical condition: cancer (malignant solid tumors)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 05:36:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA